首页> 外文期刊>The Journal of Urology >Re: Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: New insights attained by mass spectrometry: T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman, N. van Adrichem, E. Boev??, W. de Ronde, R. J. van Moorselaar and A. N. Vis J Urol 2012; 187: 1601-1607
【24h】

Re: Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: New insights attained by mass spectrometry: T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman, N. van Adrichem, E. Boev??, W. de Ronde, R. J. van Moorselaar and A. N. Vis J Urol 2012; 187: 1601-1607

机译:回复:促黄体激素释放激素激动剂治疗的睾丸激素水平低于手术去势:通过质谱获得的新见解:TM van der Sluis,HN Bui,EJ Meuleman,AC Heijboer,JF Hartman,N。van Adrichem,E。Boev ?,W。de Ronde,RJ van Moorselaar和AN Vis J Urol 2012; 187:1601-1607

获取原文
获取原文并翻译 | 示例
       

摘要

To the Editor: In this relatively small study (66 patients) the authors report that testosterone levels (measured using isotope dilution-liquid chromatography-tandem mass spectrometry) were significantly lower with gonadotropin-releasing hormone (GnRH) agonist therapy than with orchiectomy (4.0 vs 9.2 ng/dl). As highlighted in the accompanying editorial comment, the clinical relevance of such small differences is unclear. Also the surgical group was heterogeneous and included patients with prostate cancer and gender identity disorder.
机译:致编辑:在这项相对较小的研究(66例患者)中,作者报告说,促性腺激素释放激素(GnRH)激动剂治疗的睾丸激素水平(使用同位素稀释-液相色谱-串联质谱法测量)显着低于睾丸切除术(4.0 vs 9.2 ng / dl)。正如随附的社论评论所强调的那样,这种微小差异的临床意义尚不清楚。另外,手术组是异类的,包括患有前列腺癌和性别认同障碍的患者。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号